Life sciences companies are using AI to speed up drug discovery, accelerate commercialization timelines, and improve back-office functions. The strong AI market in the U.S. has allowed for collaborations between AI-focused tech companies, life sciences companies, and universities. However, limitations around centralized data availability have made for challenges with deploying technology for clinical and commercial purposes. Europe has unique advantages due to many countries having centralized health data stores, collaborative networks, and strong public funding for research. As we have seen increased investment for companies utilizing AI to improve patient outcomes, life sciences companies who can unlock cross-border collaborations in the AI space may have an edge to tap into capital markets.

As AI moves from early testing to everyday business use, companies on both sides of the Atlantic are facing major changes in how work is organized, managed, and carried out. Our panel brings together experts from Europe and the United States to explain the real challenges and opportunities that come with this shift.

Hosted by Grassi  | As U.S. Customs and Border Protection (CBP) continues to roll out the IEEPA tariff refund process, importers are facing critical, time-sensitive questions regarding eligibility, timing and compliance. With Phase 1 underway and heightened scrutiny from Customs, understanding how to prepare and how to avoid missteps is essential.

Hosted by Arendt & Medernach | This opening session, “Liquidity management tools under UCITS 6: from compliance to effective use“, will explore what UCITS 6 means in practice for liquidity risk management. We will look back at lessons learned during the initial compliance phase, discuss how to bridge the gap between regulatory disclosures and operational readiness and share an outlook on the fine-tuning required under level 2 measures, with a strong focus on real-life implementation of LMTs.